Table 4.
Three-Year Incidence of Neurocognitive Diagnoses Among Patients With Systolic HF Receiving Sacubitril/Valsartan vs Propensity Score-Matched Patients Receiving ACEIs or ARBs in Sex Subgroups
| Sacubitril/Valsartan (n = 7,505)a |
ACEI/ARB (n = 7,505)a |
HR (95% CI) | P Value | |||
|---|---|---|---|---|---|---|
| Events | 3-y K-M Estimate | Events | 3-y K-M Estimate | |||
| Men | ||||||
| Primary endpoint | 556 | 10.4% | 796 | 14.9% | 0.68 (0.61-0.75) | <0.001 |
| Cognitive decline | 490 | 9.2% | 711 | 13.1% | 0.67 (0.60-0.75) | <0.001 |
| Dementia | 179 | 3.2% | 268 | 4.8% | 0.67 (0.55-0.81) | <0.001 |
| Alzheimer | 42 | 0.7% | 56 | 1.0% | 0.76 (0.51-1.13) | 0.177 |
| Sacubitril/Valsartan (n = 3,799)a |
ACEI/ARB (n = 3,799)a |
HR (95% CI) | P Value | |||
|---|---|---|---|---|---|---|
| Events | 3-y K-M Estimate | Events | 3-y K-M Estimate | |||
| Women | ||||||
| Primary endpoint | 301 | 11.3% | 391 | 14.0% | 0.77 (0.66-0.90) | 0.001 |
| Cognitive decline | 276 | 10.1% | 342 | 12.0% | 0.81 (0.70-0.95) | 0.011 |
| Dementia | 100 | 3.7% | 156 | 5.4% | 0.66 (0.52-0.85) | 0.001 |
| Alzheimer’s disease | 14 | 0.5% | 47 | 1.6% | 0.31 (0.17-0.56) | < 0.001 |
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; HF = heart failure; K-M = Kaplan-Meier.
a
Patients with prevalent diagnoses of interest at baseline were excluded from calculation of incidence for each analysis.